S3E17: FDA grants approval to Visby Medical’s Sexual Health Click Test
Hear from Visby’s Chief Medical Officer, Gary Schoolnik, MD, about the Sexual Health Click Test.
Visby Medical’s Sexual Health Click Test is unlike anything else on the market. With a self- or health care-provided vaginal swab sample, the test can recognize three of the most common STIs—chlamydia, gonorrhea, and trichomoniasis—in 30 minutes or less.
Watch this interview and learn more about the Sexual Health Click Test here.
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
Bonus episode: Alternatives to hysterectomy & uterine-preserving options for fibroids, part 2
December 22nd 2022This is part 2 of a 2-part series. In this bonus episode of Pap Talk, get an exclusive recap of Kimberly Kho, MD's presentation from AAGL 2022 on alternatives to hysterectomy and uterine-preserving options for fibroids.
Listen
Trends in STI prevalence and testing guidelines
April 11th 2024In a recent interview, Cheruba Prabakar, MD, FACOG, shed light on the rising prevalence of sexually transmitted infections in the United States and the need for improved awareness and testing, particularly for overlooked conditions such as trichomoniasis.
Read More
Bonus episode: Alternatives to hysterectomy & uterine-preserving options for fibroids, part 1
December 21st 2022This is part 1 of a 2-part series. In this bonus episode of Pap Talk, get an exclusive recap of Kimberly Kho, MD's presentation from AAGL 2022 on alternatives to hysterectomy and uterine-preserving options for fibroids.
Listen
NIH study finds long-acting ART safe for HIV suppression in adolescents
March 7th 2024Research presented at the 2024 Conference on Retroviruses and Opportunistic Infections reveals that long-acting injectable antiretroviral therapy provides improved HIV suppression with minimal adverse effects, offering a promising alternative for adolescents and individuals struggling with daily oral regimens.
Read More
